We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+37.69%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$251M
AUM Growth
+$67.1M
Cap. Flow
+$49.6M
Cap. Flow %
19.75%
Top 10 Hldgs %
55.61%
Holding
35
New
7
Increased
11
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$14.7M
2
KURA icon
Kura Oncology
KURA
+$12.3M
3
DYN icon
Dyne Therapeutics
DYN
+$8.32M
4
CBAY
Cymabay Therapeutics
CBAY
+$8.06M
5
KALV
KalVista Pharmaceuticals
KALV
+$5.64M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$6.03M
2
SURF
Surface Oncology, Inc. Common Stock
SURF
+$4.32M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$4.26M
4
IMVT icon
Immunovant
IMVT
+$3.87M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 95.54%
2 Financials 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$730M
$25.9M 10.32%
1,028,084
-308,191
-23% -$6.03M
CCCC icon
2
C4 Therapeutics
CCCC
$376M
$17.8M 7.09%
481,094
– –
KURA icon
3
Kura Oncology
KURA
$922M
$14.7M 5.87%
521,555
+388,052
+291% +$12.3M
STSA
4
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$14.4M 5.72%
+2,431,705
New +$14.7M
FPRX
5
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$13.6M 5.42%
361,344
-170,656
-32% -$4.26M
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$13.5M 5.4%
2,983,513
+1,497,406
+101% +$8.06M
COGT icon
7
Cogent Biosciences
COGT
$6.79B
$11.1M 4.44%
1,269,195
+509,170
+67% +$4.9M
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$10.7M 4.26%
1,729,041
+454,780
+36% +$2.76M
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.75B
$9.05M 3.61%
349,600
+2,100
+0.6% +$53.1K
KRON
10
DELISTED
Kronos Bio
KRON
$8.75M 3.48%
298,839
– –
CNST
11
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$8.62M 3.43%
368,448
-55,260
-13% -$1.67M
TRIL
12
DELISTED
Trillium Therapeutics Inc.
TRIL
$8.55M 3.41%
795,868
-57,003
-7% -$705K
VTGN icon
13
VistaGen Therapeutics
VTGN
$9.29M
$7.94M 3.16%
124,323
+19,323
+18% +$1.29M
GNCA
14
DELISTED
Genocea Biosciences, Inc.
GNCA
$7.78M 3.1%
2,871,624
+1,105,723
+63% +$3.27M
CLDX icon
15
Celldex Therapeutics
CLDX
$2.77B
$7.62M 3.04%
369,951
+13,520
+4% +$310K
MRSN
16
DELISTED
Mersana Therapeutics
MRSN
$6.95M 2.77%
17,169
+10,816
+170% +$5.25M
MREO
17
Mereo BioPharma
MREO
$45.9M
$6.9M 2.75%
2,048,757
+194,479
+10% +$687K
DYN icon
18
Dyne Therapeutics
DYN
$4.04B
$6.68M 2.66%
+430,112
New +$8.32M
RLMD icon
19
Relmada Therapeutics
RLMD
$544M
$5.69M 2.27%
161,565
-17,000
-10% -$595K
KALV
20
DELISTED
KalVista Pharmaceuticals
KALV
$5.51M 2.19%
+214,467
New +$5.64M
XENE icon
21
Xenon Pharmaceuticals
XENE
$6.32B
$5.39M 2.15%
301,392
-165,976
-36% -$2.81M
SNDX icon
22
Syndax Pharmaceuticals
SNDX
$1.84B
$5.29M 2.11%
236,500
-93,815
-28% -$2.12M
EPIX
23
DELISTED
ESSA Pharma
EPIX
$5.14M 2.05%
+176,821
New +$4.11M
SPRY icon
24
ARS Pharmaceuticals
SPRY
$590M
$4.24M 1.69%
97,143
– –
PMVP icon
25
PMV Pharmaceuticals
PMVP
$66.1M
$4.11M 1.64%
125,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Commodore Capital held 35 positions worth $251M, up 36% from $184M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Commodore Capital deployed $49.6M of net new capital in Q1 2021, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Satsuma Pharmaceuticals, Inc. Common Stock: 2,431,705 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $6.03M trimmed.

  • Commodore Capital's largest Q1 2021 buy was Satsuma Pharmaceuticals, Inc. Common Stock: 2,431,705 shares worth $14.4M.
  • Commodore Capital added most to Kura Oncology in Q1 2021, an estimated $12.3M increase.
  • Commodore Capital's biggest Q1 2021 reduction was Aclaris Therapeutics, cutting an estimated $6.03M.
  • Commodore Capital fully exited Surface Oncology, Inc. Common Stock in Q1 2021, selling an estimated $4.32M.
  • Commodore Capital's ten largest holdings make up 56% of its $251M portfolio in Q1 2021.
  • Commodore Capital opened 7 new positions and closed 4 in Q1 2021.
  • Commodore Capital's portfolio value rose 36% quarter-over-quarter to $251M.

Based on Commodore Capital's 13F filing for Q1 2021, filed 17 May 2021.